- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Small HER2 Positive Breast Cancer: When is Enough? ; volume:39 ; number:01 ; year:2018 ; pages:1-3
Indian journal of medical & paediatric oncology ; 39, Heft 01 (2018), 1-3
- Beteiligte Personen und Organisationen
-
Singh, Randeep
Gupta, Sudeep
- DOI
-
10.4103/ijmpo.ijmpo_12_17
- URN
-
urn:nbn:de:101:1-2021082610202496143740
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Singh, Randeep
- Gupta, Sudeep
Ähnliche Objekte (12)
Targeted therapy for HER2 positive breast cancer
PYK2 promotes HER2-positive breast cancer invasion
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
When ‘Enough and as Good’ is Not Good Enough
When Discrimination is Not Enough
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Targeted therapy for HER2 positive breast cancer
PYK2 promotes HER2-positive breast cancer invasion
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
When ‘Enough and as Good’ is Not Good Enough
When Discrimination is Not Enough
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Targeted therapy for HER2 positive breast cancer
PYK2 promotes HER2-positive breast cancer invasion
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
When ‘Enough and as Good’ is Not Good Enough
When Discrimination is Not Enough
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer